Sponsored Content | Case Study | Radiation Therapy | May 29, 2019

Radiotherapy Program Thrives Amid Major Patient Volume Increases

The Ottawa Hospital in Canada and Elekta partner to boost radiotherapy efficiency

Versa HD

Elekta's Versa HD

The so-called “Grey Tsunami” of baby boomers using healthcare services isn’t taking the Radiation Medicine Program at The Ottawa Hospital (TOH, Ottawa, Ontario) by surprise. The medical center began acquiring the extra needed cancer treatment resources in 2009, when the hospital entered a partnership agreement with Elekta to reinforce its radiotherapy capacity with additional linear accelerators and software. Ten years later — despite a major increase in radiotherapy patient volume — the Radiation Medicine Program is a model of efficiency and TOH is acquiring three of the company’s Versa HD high definition digital accelerators.

“Our volume has grown 30 percent in the last decade, and that’s mainly due to an increase in the cancer incidence among individuals in their mid-50s to mid-70s — the baby boomer generation,” said Jason Pantarotto, M.D., head, Radiation Medicine Program at TOH, which has radiation therapy services at its General Campus and Queensway Carleton Hospital. “But it’s also a result of our efforts to ensure that every patient in our region has access to radiotherapy services.”

More than 85,000 people receive a cancer diagnosis in Ontario each year; TOH treats 4,600 cases with radiation annually.

Today TOH operates over a dozen treatment machines, including several Elekta Synergy digital accelerators and one Versa HD system, the latter treating clinically for about two months. Another Versa HD is currently being installed to treat patients by June and a third will be installed later this year.

 

Standardizing Increases Efficiency

Diversity is often viewed as a plus in many areas, but in the context of radiotherapy equipment, standardizing on Elekta products has been the key to TOH’s strategy to boost efficiency as patient volumes rise.

“Increased efficiency is a top priority,” Pantarotto observed. “Previously, we had different linacs and radiotherapy software from various vendors. The need to shift a patient between systems happens all the time at radiation oncology clinics, and then you have to re-plan the patient. Now, all of our linacs are Elekta systems and they’re all beam-matched — from the first Elekta Synergy systems we acquired years ago to the new Versa HD machines coming in — which means we can effortlessly switch a patient to a different machine if necessary.”

 

VMAT Speeds Daily Throughput

With its complement of matched, advanced digital accelerators and Elekta’s Monaco treatment planning system, TOH has been able to steadily shift from relatively slower treatment delivery techniques to faster volumetric modulated arc therapy (VMAT). Today, 60 percent of all cases are treated with VMAT, according to Pantarotto.

“We’ve passed an inflection point where it’s less complex now to deliver VMAT than some of the older delivery techniques, such as step-and-shoot IMRT and 3-D conformal, which were common in the past,” he said. “VMAT planning is far more efficient and the therapists tell us they find VMAT delivery more efficient than traditional methods. And that’s for simple palliative cases as well as for the complex ones.”

In this respect, the radiotherapy team gains not only speed, but a uniform process for all TOH team members to follow, regardless of the patient type or time of day.

“Our future vision is to use
VMAT even for our on-call emergency patients, because a homogenous process that everyone is familiar with is a safer process,” Pantarotto observed.

 

Faster Planning

TOH’s planning of VMAT cases with Monaco boosts efficiency at the start, he added.

“Case planning is faster, which allows the planner to not only create better plans via Monaco software, but they also can run multiple iterations at the radiation oncologist’s request,” he explained. “That’s valuable from the physician’s perspective. We’re seeing beautiful plans, and that has made us rethink how we treat patients. We’re thinking of the immediate future and devising how we might be able to give even more dose in a shorter time and evaluating that in clinical trials. We wouldn’t be in this mindset if we didn’t have a tool like Monaco.”

 

Radiotherapy Frontline Treatment for More Cases

The ability to perform precise, efficient treatments with its Elekta solutions has added to TOH’s workload as much as Grey Tsunami demographics, according to Pantarotto.

“There are disease sites that we see more of over time,” he said. “For example, patients with Stage I lung cancer or liver cancer are increasingly diverted from the OR to the linac. These are patients that would not otherwise have been in the clinic a decade ago. In addition, stereotactic body radiation therapy (SBRT) continues to rise in popularity at TOH. Last year, we performed 230 lung SBRT treatments, whereas in 2009 it was no more than 50. A treatment that in the past once took 45 minutes for a single tumor, we now routinely treat two, three or even four lung nodules at the same time.”

SBRT also is increasingly used for prostate, adrenal glands and periaortic lymph nodes. As a result of more efficient planning and delivery, patient wait times for treatment have improved substantially.

“Over the last seven years, we have scrutinized every step in the planning process,” he said. “With Monaco we are finding we can develop complex, high-quality plans faster than ever before. Now, instead of starting with a somewhat crude plan, we can start with a very sophisticated plan very quickly and save us the work of re-planning the patient a few days later.”

As TOH continues its partnership with Elekta, Pantarotto is looking forward to ongoing improvements in his program’s efficiency and sophistication.

“We view Elekta as a true partner in cancer care for the patients of Ottawa and our region,” he said. “As providers, we face challenges that evolve over time and the same is true for Elekta as a vendor. Over several years, our relationship has grown such that we feel our experience can help Elekta develop products that are even more useful for the future, and that usefulness will translate to safer, more effective and efficient radiotherapy for our patients.”

Related Content

MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI.

MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI. Image courtesy of Exact Imaging

Feature | Prostate Cancer | January 20, 2021 | By Brian Wodlinger, Ph.D.
Historically when a patient had an elevated PSA (prostate specific antigen) test their urologist would take the next
The exceptionally high dose rate of the FLASH Beam is 3,000 times higher than normal therapy treatment (300 Gray per second vs. 0.1 Gray per second, Gray being a standard unit measuring absorbed radiation). Instead of treatment over 20 seconds, an entire treatment is completed in 6 milliseconds, giving the therapy its nickname, "FLASH." Image courtesy of Brian Pogue, PhD

The exceptionally high dose rate of the FLASH Beam is 3,000 times higher than normal therapy treatment (300 Gray per second vs. 0.1 Gray per second, Gray being a standard unit measuring absorbed radiation). Instead of treatment over 20 seconds, an entire treatment is completed in 6 milliseconds, giving the therapy its nickname, "FLASH." Image courtesy of Brian Pogue, PhD

News | Linear Accelerators | January 20, 2021
January 20, 2021 — A joint team of researchers from Radiation Oncology at Dartmouth's and...
Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast by Type; PET Product" report has been added to ResearchAndMarkets.com's offering. The prostate cancer nuclear medicine diagnostics market in the US was valued at $194.47M in 2019 and is expected to grow at a CAGR of 10.6% from 2020 to 2027 to reach $431.76M by 2027.

Getty Images

News | Prostate Cancer | January 13, 2021
January 13, 2021 — The ...
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

News | Prostate Cancer | January 11, 2021
January 11, 2021 — A study
Mirion Technologies, Inc., a global provider of innovative radiation detection and measurement solutions, announced that it has acquired Sun Nuclear Corporation. Sun Nuclear is the global leader in radiation oncology quality assurance, delivering patient safety solutions for diagnostic imaging and radiation therapy centers around the world.
News | Quality Assurance (QA) | January 08, 2021
January 8, 2021 — Mirion Technologies, Inc., a global provider of
RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular healthcare solutions in 2021 with the introduction of a compact shielding facility designed to accommodate the latest models of low energy, self-shielded linear accelerators (linacs) that are now available worldwide. 

Image courtesy of Siemens Healthineers

News | Linear Accelerators | January 04, 2021
January 4, 2021 — RAD Technology Medical Systems (RAD) ann
RaySearch Laboratories AB has launched the latest release of its widely adopted treatment planning system. RayStation 10B adds support for brachytherapy planning and a new GPU Monte Carlo algorithm, which typically cuts final dose computation times to less than five seconds.
News | Brachytherapy Systems | December 29, 2020
December 29, 2020 — RaySearch Laboratories AB has launched the latest release of its widely adopted treatment plannin
C-RAD has been selected as the partner to implement surface tracking technology for three proton cancer treatment centers in the U.S.
News | Proton Therapy | December 28, 2020
December 28, 2020 — C-RAD offers a specific version of its Catalyst System for use in...